 |
|
Administration of Recombinant Activated Factor VII in Major Thoracic Operations
Ali-Asghar Alavi, MD;
Sayed Mahdi Jalali, MD;
Mohammad R. Rasouli, MD;
Payam Eghtesadi-Araghi, MD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
We would like to make some points regarding the valuable article by Ranucci et al1 published in the March issue of the Archives. The authors reviewed randomized clinical trials of the administration of recombinant factor VII (rFVII) in major operations. In their meta-analysis, they showed that, in major operations, rFVII can reduce use of red blood cell units. Most of these studies have been performed in cardiac operations and liver transplantation. In some major operations, such as thoracic operations, we do not have enough evidence2 about the efficacy and safety of rFVII. In a randomized controlled trial, we evaluated the effect of rFVII on 40 patients who underwent elective thoracic operations (20 of whom received 90 µg of rFVII per kilogram of bodyweight preoperatively). In our study, there were no significant differences regarding perioperative bleeding . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Efficacy and Safety of Recombinant Activated Factor VII in Major Surgical Procedures: Systematic Review and Meta-analysis of Randomized Clinical Trials
Marco Ranucci, Giuseppe Isgrò, Giorgio Soro, Daniela Conti, and Barbara De Toffol
Arch Surg. 2008;143(3):296-304.
ABSTRACT
| FULL TEXT
RELATED LETTER
Administration of Recombinant Activated Factor VII in Major Thoracic Operations—Reply
Marco Ranucci
Arch Surg. 2008;143(10):1021.
EXTRACT
| FULL TEXT
|
